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Abstract 
Background: Skeletal dysplasia are genetic disorders of cartilage and bone, characterized by impairments com-
monly resulting in short stature, altered movement biomechanics, pain, fatigue and reduced functional performance. 
While current tools quantify functional mobility performance, they have not been standardly used in this population 
group and do not capture patient-reported symptoms such as pain or fatigue. This study evaluated a new tool, the 
Screening Tool for Everyday Mobility and Symptoms (STEMS), designed to accurately and objectively assess functional 
mobility and associated symptomology for individuals with skeletal dysplasia.
Methods: Individuals aged 5–75 years with a skeletal dysplasia completed the STEMS, the Functional Mobility Scale 
(FMS) and Six Minute Walk Test (6MWT). The correlation among the STEMS, use of mobility aides, FMS and 6MWT 
normalised for leg length was calculated. One-way analysis of variance compared the STEMS symptomatology to 
normalised 6MWT distance.
Results: One hundred and fifty individuals with skeletal dysplasia (76 achondroplasia, 42 osteogenesis imperfecta, 
32 other; 74 < 18 years, 76 ≥ 18 years) participated. Almost two thirds of the group reported pain and/or fatigue 
when mobilising at home, at work or school and within the community, but only twenty percent recorded use of a 
mobility device. The STEMS setting category demonstrated highly significant correlations with the corresponding 
FMS category (r = − 0.983 to − 0.0994, all p < 0.001), and a low significant correlation with the normalised 6MWT 
distance (r = − 0.323 to − 0.394, all p < 0.001). A decreased normalised 6MWT distance was recorded for individuals 
who reported symptoms of pain and/or fatigue when mobilising at home or at work/school (all p ≤ 0.004). Those who 
reported pain only when mobilising in the community had a normal 6MWT distance (p = 0.43–0.46).
Conclusions: The Screening Tool for Everyday Mobility and Symptoms (STEMS) is a useful new tool to identify and 
record mobility aide use and associated self-reported symptoms across three environmental settings for adults and 
children with skeletal dysplasia. The STEMS may assist clinicians to monitor individuals for changes in functional 
mobility and symptoms over time, identify individuals who are functioning poorly compared to peers and need fur-
ther assessment, and to measure effectiveness of treatment interventions in both clinical and research settings.
Keywords: Skeletal dysplasia, Mobility, Pain, Fatigue, Achondroplasia, Osteogenesis imperfecta, Functional mobility 
tool
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Skeletal dysplasia occur in approximately 1 in every 
5000 births, and incorporate over 350 individual dis-
orders affecting cartilage and bone, the most common 
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of which is achondroplasia [1]. There are several well 
recognised musculoskeletal impairments associated 
with skeletal dysplasia including short stature, macro-
cephaly, altered lower limb alignment, and scoliosis [2–
4]. Disproportionate growth between the long bones 
and the underlying structures can lead to a number of 
orthopaedic, neurological, respiratory, ear, nose and 
throat and dental issues for individuals with skeletal 
dysplasia [3–5]. Furthermore, the complex interplay of 
the characteristic impairments of body structure can 
contribute directly and cyclically to activity limitations 
and participation restrictions for individuals with skel-
etal dysplasia across several areas of mobility, physical 
activity and day to day functioning [5, 6].
There is limited literature outlining the medical, 
health and social aspects of life for adolescents and 
adults with skeletal dysplasia, particularly in relation to 
their physical function and mobility. While some infor-
mation is available regarding targeted profiles of motor 
skill development in children for varying forms of skel-
etal dysplasia such as achondroplasia [7–10] and oste-
ogenesis imperfecta [11, 12], several research groups 
have highlighted issues with functional capacity post 
childhood. A significant number of adults with skeletal 
dysplasia develop physical limitations, pain and fatigue 
which impacts on their quality of life [13–17]. Recent 
studies have more specifically considered the relation-
ship between pain and function and noted that chronic 
pain is prevalent in individuals with skeletal dysplasia, 
and associated with poor physical function [18, 19]. 
However, the specific impact that pain and/or fatigue 
has on mobility remains unclear.
The complex relationship existing between functional 
mobility performance and associated symptoms such as 
pain and fatigue for individuals with varying forms of 
proportionate and disproportionate short stature is cur-
rently not accurately reflected through use of existing 
objective clinical assessments or patient-reported ques-
tionnaires. While tools such as the Functional Mobil-
ity Scale (FMS) [20] and the Bleck Score [21] objectively 
capture utilisation of mobility devices or equipment 
across distances (5, 50 and 500  m) or settings (therapy, 
household, neighbourhood, community) respectively, 
they do not capture patient reported variables such as 
pain or fatigue that may impact upon mobility perfor-
mance across different settings (home, school/work and 
community). Evaluation of patient reported outcomes 
is essential when considering the overall health status 
of an individual [22], and while the recently developed 
PROMIS tools provide questions regarding mobility, pain 
and fatigue [23], the impact of symptoms on mobility in 
different settings is not covered within the current item 
banks.
This study is proposing a functional mobility scale 
specifically for individuals with skeletal dysplasia. The 
purpose of this scale is to assist clinicians to objectively 
classify functional mobility, reflecting varying abili-
ties across different real-world environment constructs 
(home, school/work, community), as well as capturing 
patient reported symptomatology such as pain or fatigue 
associated with this. The Screening Tool for Everyday 
Mobility and Symptoms (STEMS) considers functional 
mobility across different settings, and with varying types 
of mobility aides, in a similar method to FMS. However, 
the proposed scale also records and reflects the presence 
of symptoms such as pain and/or fatigue that impact 
activity levels for individuals with skeletal dysplasia. This 
allows clinicians to record the actual performance for the 
individual and capture patient-reported consequences. 
The recording of clinically relevant secondary outcomes 
such as pain and fatigue related to functional mobil-
ity level allows health care workers to assess and record 
changes that occur through provision of environmental 
modifications, equipment, rehabilitation programmes or 
medical and surgical interventions. The opportunity to 
provide a standardised screening tool to monitor every-
day mobility and symptoms has potential for use as an 
efficacy end-point in future long-term clinical drug trials 
[24].
The aim of this study was to validate the screening tool 
(Screening Tool for Everyday Mobility and Symptoms; 
STEMS) by comparing the performance of a group of 
children and adults with skeletal dysplasia using STEMS 
with a contemporaneous mobility assessment of the same 
individuals using FMS and 6 min Walk Test (6MWT).
Method
Study design and participants
This cross-sectional study involved 150 Australian chil-
dren and adults with any form of skeletal dysplasia aged 
between 5 and 75 years (recruited from August 2017 to 
November 2019). Individuals with any additional neuro-
logical (e.g. epilepsy, history of brain injury or cerebral 
palsy), musculoskeletal (e.g. scoliosis, recent fracture), 
respiratory or behavioural problems, which were not 
related to skeletal dysplasia, were excluded as these con-
ditions may have impacted upon functional mobility 
level. Participants were identified and recruited across 
Australia at patient organisation conferences and the 
Kids Rehab Complex Musculoskeletal Clinic at The Chil-
dren’s Hospital at Westmead, New South Wales, the 
Rehabilitation Clinic at Queensland Children’s Hospital 
Queensland, and the Bone Dysplasia Clinic at Victorian 
Clinical Genetics Services, Victoria. Ethical approval was 
obtained through the Sydney Children’s Hospitals Net-
work (HREC/16/SCHN/221) and Macquarie University 
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(Reference no. 5201700121) Human Research Ethics 
Committees. Written informed consent was obtained 
from individuals or, if under the age of 18  years, their 
parents/guardians.
Measurement tools
Functional mobility was screened through the newly 
developed Screening Tool for Everyday Mobility and 
Symptoms (STEMS) (Additional file 1). The STEMS was 
developed using a reference group of expert clinicians 
and researchers working with individuals with skeletal 
dysplasia. Expert clinicians report that mobility aides 
are often supplied to individuals with skeletal dysplasia 
to maximise participation even when an individual has 
the physical capacity to mobilise without the aid. For 
example, an individual with short stature may require a 
powered device to maintain speed when mobilising with 
normal statured peers, or an individual with bone fra-
gility may use a mobility aid to maintain safety when in 
crowded environments. Hence the scoring of an indi-
vidual’s mobility based solely on the aid used does not 
necessarily reflect their physical capacity. Furthermore, 
symptoms are commonly reported to impact on the 
daily function of individuals with skeletal dysplasia, and 
may also result in the prescription of a mobility aide in 
attempts to minimise these [25, 26]. Therefore, the scor-
ing system was developed to reflect both the usage of a 
mobility aide (reported by numbers) and the commonly 
reported clinical symptoms related to mobility levels 
(reported by letters). The STEMS considers mobility 
across different environments (home, school/work and 
community) and records usage of varying types of walk-
ing devices. The proposed STEMS also reflects pain and/
or fatigue that may influence activity levels of individu-
als with skeletal dysplasia at the end of the day. Assessors 
identify the use of mobility aides across each of the three 
settings (home, school/work and community) and record 
this as a numerical value (1–5) (Score 1 = independent 
on all surfaces including stairs, 2 = use of sticks, 3 = use 
of crutches, 4 = use of wheeled walking device, 5 = use of 
wheelchair or mobility scooter) (Table 1). Assessors then 
record the impact that mobility has on function at the 
end of the day by including patient reported symptoms. 
Each symptom was assigned a letter; A (reflecting nil 
pain or fatigue), B1 (reflecting pain only), B2 (reflecting 
fatigue only) or C (reflecting both pain and fatigue). This 
is completed for each of the three environments so the 
individual receives three scores. The number reflects the 
use of mobility aides and the letter reflects the symptoms. 
e.g. 1A, 1B1, 1C. This example represents the situation 
where an individual mobilises at home with no aide and 
no pain or fatigue altering function at the end of the day 
(1A) but reports pain   after  mobilising at work/school 
without use of aides (1B1) and both pain and fatigue after 
mobilising in the community without use of aides (1C).
Participants were also assessed using the FMS for cer-
ebral palsy, which was developed in 2004 to describe 
functional mobility in children with cerebral palsy. The 
FMS has been formally evaluated in terms of validity and 
reliability [20, 27, 28]. The FMS records the individual’s 
ability to walk a distance of 5, 50 and 500 m and uses a 
six point rating scale to record the use of assistive devices 
ranging from a score of 1 reflecting use of a wheelchair 
through to a score of 6 reflecting independent mobil-
ity on all surfaces (Table 1). The FMS was administered 
through interview by one of the researchers. Participants 
also completed the 6  min Walk Test (6MWT), a self-
paced, standardized test of endurance and walking abil-
ity which has been demonstrated to be highly reliable and 
valid in both paediatric and adult populations [29–32]. 
Participants completed this test with or without sticks, 
crutches or a wheeled walking device. Wheelchair use 
was not allowed during the 6MWT.
Procedure
Following collection of demographic data, including age, 
gender, diagnosis and any comorbidities, leg length was 
measured from the anterior superior iliac spine to the 
medial malleoli bilaterally. Standing height and weight 
was also recorded. The STEMS, FMS, and the 6MWT 
were completed by each participant under guidance from 
an experienced member of the research team. Parents/ 
Table 1 Comparison of scoring system between FMS and STEMS
FMS STEMS—aide STEMS—symptoms
1 Uses wheelchair, stroller or buggy Mobilises independently—no aide A—Nil pain or fatigue altering activity
2 Uses K-walker or other walking frame Mobilises—uses stick(s)
3 Uses two crutches Mobilises—uses crutches B1—Pain limiting activity
B2—Fatigue limiting activity
4 Uses one crutch or two sticks Mobilises—uses wheeled walking device
5 Independent on level surfaces Wheelchair or power mobility scooter C—Pain and fatigue limiting activity
6 Independent on all surfaces N/A
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guardians of younger children assisted in the comple-
tion of the STEMS and FMS. No direct age cut-off was 
used for parent or child-report, as a pragmatic approach 
was taken whereby the child was asked first and par-
ent/guardian only contributed if the child was unable to 
answer.
Data analysis
Analysis was conducted using SPSS for Mac (Version 26, 
Chicago, IL, USA). Data was examined visually and con-
firmed to be normally distributed, with the mean, stand-
ard deviations and frequencies calculated to describe 
the participant population. To account for differences in 
stature and proportions between individuals with skeletal 
dysplasia, all 6MWT total distances were normalised by 
dividing the total 6MWT distance by the average of the 
participants left and right leg length (metres).
To determine the usefulness of the STEMS to record an 
individuals’ functional mobility, including usage of mobil-
ity devices across three primary environments (home, 
school/work, community), the association between the 
STEMS and the FMS and the normalised 6MWT was 
undertaken using Pearson’s correlation coefficient. The 
correlation between the STEMS and each of the compar-
ison tests (FMS and 6MWT) was defined as large if the 
correlation was 0.5–1.0, medium if 0.3—0.49 and small if 
0.1–0.29 [33].
To identify and record the impact of additional symp-
tomatology (pain and/or fatigue) on participation perfor-
mance, two one-way between-groups analyses of variance 
(ANOVA) were conducted to explore the impact of i) 
symptom classifications (A, B1, B2 and C), and ii) num-
ber of symptoms (no symptoms (A), one symptom (B1 
or B2), 2 symptoms (C)) within each of the three envi-
ronments, on the normalised 6MWT distance. Impact of 
symptoms was explored within the total group of individ-
uals with skeletal dysplasia, and due to sufficient sample 
size, also within the achondroplasia diagnostic category. 
Effect sizes were calculated using eta squared with 0.01 
considered a small effect, 0.04 a medium effect and 0.14 a 
large effect [34]. When significant differences were noted, 
post hoc comparisons were performed with the Tukey 
HSD test to determine whether a particular symptom, 




One hundred and fifty individuals with varying forms 
of skeletal dysplasia from across Australia enrolled in 
the study. Efforts were made to recruit approximately 
equal numbers of males and females across each five 
year (paediatric/adolescent) and ten year (adult) age 
bracket. Eighty four individuals (36 males) were clas-
sified as children or adolescents aged between 5 and 20 
years with the remaining sixty-six (21 males) classified as 
adults (> 20 years). Participants were classified into three 
main groups based on diagnosis (numbers). Seventy-six 
individuals (28 males) had achondroplasia, forty-two 
individuals (14 males) had osteogenesis imperfecta and 
thirty two individuals (15 males) reported another form 
of skeletal dysplasia (Table 2). The ‘other’ group included 
thirty two individuals with forms of skeletal dysplasia 
classified as; (1) conditions causing short limbs at birth/
infancy (including Spondyloepiphyseal dysplasia con-
genita (SEDC), pseudoachondroplasia, Spondyloepimet-
aphyseal dysplasia-Strudwick (S’E’MD-Strudwick), 
Diastrophic Dysplasia); (2) conditions causing short stat-
ure in later childhood (Metaphyseal chondrodysplasia 
type Schmid (MCDS), Leri Weil Dysplasia); (3) condi-
tions affecting epiphyses (Multiple epiphyseal dysplasia 
(MED); (4) disorders with short hands/feet (Geleophysic 
dysplasia) and v) disorders that cause small chest size 
(Ellis can Creveld, Jeune asphyxiating thoracic dysplasia) 
[1]. The age-sex distribution and diagnostic groupings are 
reported in Table  2 and the mean heights are reported 
in Table  3. Eighty percent of the cohort (45 males; 75 
females) were considered as short statured (less than 3rd 
centile height).
The FMS assessment [20] was used to describe func-
tional mobility both for the total group and for each of 
the three major groupings (achondroplasia, osteogenesis 
imperfecta and Other) (Table 4). Across the total cohort 
there was a decrease in the number of 5/6 ratings (inde-
pendent without walking aides) across 5, 50 and 500  m 
with a corresponding increase in the number of rating 
1 (use of wheelchair, stroller or buggy) scores across the 
three distances. One fifth of the total cohort reported 
using a wheelchair or power mobility scooter over a 
distance of 500  m with 68% of wheelchair users being 
children.
The 6MWT was not attempted by 5 individuals, who 
were unable to weightbear beyond standing transfers, 
all of whom had OI. The mean distance covered by the 
remaining 145 individuals was 414 m (range 20–705, SD 
121  m; normalised 6MWT mean = 757, range 23–1347, 
SD 234 m). Nine participants including eight with OI and 
one with pseudoachondroplasia used a walking aide dur-
ing the 6MWT.
Correlations of the STEMS with FMS and 6 MWT
Using Pearson’s rank correlations, the walking aids used 
across STEMS environment category demonstrated large 
significant negative correlations with the FMS tool: (1) 
STEMS—Home and FMS—5  m (r = − 0.968, p < 0.001); 
(2) STEMS—School/work and FMS—50  m (r = − 0.983, 
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p < 0.001) and (3) STEMS—Community and FMS—
500 m (r = − 0.994, p < 0.001). There was a medium nega-
tive significant correlation between the STEMS setting 
categories and the normalised 6MWT (r = − 0.323—-
0.394, all p < 0.001).
Symptomatology
Across the total cohort, there was a decrease in the 
number of participants reporting no symptoms (Score 
A) across home, school/work and the community with 
an increase in the number of participants reporting 
one symptom (either pain (B1) or fatigue (B2)) and two 
symptoms (pain and fatigue (C)) across each of the three 
environments (Fig. 1). Twenty percent of the total group 
reported symptoms of pain and fatigue that altered 
function associated with mobility around the home, ris-
ing to approximately one half indicating both pain and 
fatigue influencing function at the end of day associated 
with mobility around the community. The percentage 
of individuals reporting either pain or pain and fatigue 
increased from 28% within the home environment, to 
42% within the school/work setting, and peaked at 62.6% 
resulting from community mobility. Across the diagnos-
tic groups individually, individuals reporting both pain 
and fatigue in the community encompassed 44% of all 
individuals with achondroplasia, 81% of all individuals 
with OI and 38% of individuals with other skeletal dys-
plasia. Furthermore, 62% of the OI cohort reported two 
symptoms (Score C) compared with 50% of the Other 
group and 43% of the achondroplasia group (Fig. 1) when 
considering mobility within the community.
STEMS mobility aide and symptom classifications of all 
participants and participants within each diagnostic cat-
egory, across different environments.
When considering the overall cohort, there was a mod-
erate statistically significant difference in the normalised 
Table 2 Demographics and skeletal dysplasia diagnosis by gender and age in adults and children/adolescents (n = 150)
Child/adolescent Adults
5–10 years 11–15 years 16–20 years 21–30 years 31–40 years 41–50 years  > 51 years
M F M F M F M F M F M F M F
Achondroplasia 15 15 4 7 5 5 1 5 0 6 3 5 0 5
Osteogenesis imperfecta 4 2 0 6 3 2 3 1 2 8 2 4 0 5
SEDC 0 2 1 0 1 1 2 1 0 0 2 0 0 1
Cartilage hair hypoplasia 0 1 0 0 0 0 0 0 1 0 0 0 0 0
Pseudochondroplasia 1 0 0 0 0 0 0 0 0 0 0 0 1 1
Hypochondroplasia 0 0 0 0 0 0 0 1 1 0 0 0 0 0
Primordial dwarfism 0 1 0 0 0 0 0 0 1 0 0 0 0 0
S’E’MD-Strudwick 0 1 1 0 0 0 0 0 0 0 1 0 0 0
Diastrophic dysplasia 0 2 0 0 0 0 0 0 0 0 0 0 0 0
Metaphysealchondro- dysplasia Schmid 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Leri-Weil dysplasia 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Multiple epiphyseal dysplasia 0 1 1 0 0 0 0 0 0 0 0 0 0 0
Geleophysic dysplasia 0 0 0 0 0 0 0 0 1 0 0 0 0 0
Jeune syndrome 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Ellis-van Creveld syndrome 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Other—total 1 8 3 2 1 1 2 2 4 1 3 1 1 2
Total 20 25 7 15 9 8 6 8 6 15 8 10 1 12
Table 3 Heights and deviations by skeletal dysplasia diagnosis for adults and children/adolescents
Dysplasia Height in cm (range (mean ± SD))
Total N Adult Child/adolescent
Total 150 84.8–176.3 (133.8 ± 19.9) 77.8–175 (115.9 ± 22)
Achondroplasia 76 110–135 (125 ± 6.2) 83–149.9 (107.1 ± 14.8)
Osteogenesis imperfecta 42 84.8–176.3 (145.4 ± 25.1) 114.4–175 (142.5 ± 15.8)
Other 32 111–170 (128.9 ± 16) 77.8–154.5 (115.8 ± 24.6)
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6MWT distances achieved by individuals reporting 
zero, one or two symptoms (F(2,142) = 8.25,  eta2 = 0.1, 
p = 0.001) and within each of the symptom classifications 
(F(3,141) = 5.48,  eta2 = 0.1, p < 0.001) when mobilising 
around the home (Fig. 2). Post-hoc analysis demonstrated 
that individuals presenting with no symptoms (A) walked 
a significantly larger normalised 6MWT distance than 
individuals reporting one (mean difference 145.3 m, 95% 
CI 37.9–252.8 m) or two (mean difference 164.4 m, 95% 
CI 47.3–281.4  m) symptoms. Fatigue (mean difference 
139.6 m, 95% CI 3.4–275.9 m) or pain and fatigue (mean 
difference 164.4  m, 95% CI 47.3–281.4  m) but not pain 
alone (mean difference 157.2 m, 95% CI − 26.8–341.2 m) 
reported to limit their ability around the home, signifi-
cantly reducing the walking distances achieved on the 
6MWT.
Moderate significant differences were also demon-
strated when considering the limiting symptoms in the 
school/work environment and the normalised 6MWT 
distances (F = 4,53–6.89,  eta2 = 0.09, p = 0.001–0.004). 
Individuals reporting pain and fatigue (mean difference 
165.5  m, 95% CI 48.8–282.2  m), walked significantly 
lower distances than individuals reporting no symptoms.
No significant differences in the 6MWT distances 
were achieved between individuals reporting each of 
the different symptom classifications (F(3,141) = 0.86, 
n = 0.02, p = 0.46) as well as numbers of symptoms 
(F(2,142) = 0.64,  eta2 = 0.12, p = 0.42) limiting commu-
nity mobility.
The achondroplasia cohort also demonstrated a mod-
erate statistically significant difference in the normalised 
6MWT distances achieved by individuals reporting zero, 
one or two symptoms (F(2,73) = 4.96, n = 0.12, p = 0.01) 
and within each of the symptom classifications (F(3, 
72) = 3.44, n = 0.12, p = 0.02) when mobilising around 
the home (Fig.  2). Post-hoc analysis also demonstrated 
that individuals presenting with no symptoms (A) walked 
a significantly larger normalised 6MWT distance than 
individuals reporting one (mean difference 116.3 m, 95% 
CI 2.1–230.6 m) or two (mean difference 148 m, 95% CI 
7.4–288.6 m) symptoms limiting their ability to mobilise 
around the home. However, post-hoc testing demon-
strated no significant differences between the symptom 
classifications. There were no significant differences in 
the normalised 6MWT distance and reporting of symp-
toms limiting the work/school and community setting 
(F = 0.42–6.36,  eta2 = 0.02–0.07, p = 0.06–0.74).
Normalised six minute walk distances covered by indi-
viduals based on symptomatology.
Discussion
This study describes a new screening tool (acronym 
“STEMS”) that allows clinicians to record mobility 
aide usage and patient-reported pain and fatigue while 
mobilising in three environments encountered in eve-
ryday life. There are currently no other tools for this for 
individuals with skeletal dysplasia. Clinical manage-
ment focuses on maximising functional capacity which 
Table 4 Functional mobility scale for study cohort
Rating Total (n/%) Achondroplasia (n/%) Osteogenesis imperfecta 
(n/%)
Other (n/%)
FMS-5 1 6 (4) 0 (0) 5 (11.9) 1 (3.1)
2 2(1.3) 0 (0) 1 (2.4) 1 (3.1)
3 2 (1.3) 0 (0) 1 (2.4) 1 (3.1)
4 2 (1.3) 1 (1.3) 0 (0) 1 (3.1)
5 12 (8) 6 (7.9) 5 (11.9) 1 (3.1)
6 126 (84) 69 (90.8) 30 (71.4) 27 (84.4)
FMS-50 1 13 (8.7) 1 (1.3) 9 (21.4) 3 (9.4)
2 1 (0.7) 0 (0) 0 (0) 1 (3.1)
3 3 (2) 0 (0) 2 (4.8) 1 (3.1)
4 5 (3.3) 1 (1.3) 2 (4.8) 2 (6.3)
5 9 (6) 6 (7.9) 2 (4.8) 1 (3.1)
6 119 (79.3) 68 (89.5) 27 (64.3) 24 (75)
FMS- 500 1 31(20.7) 8 (10.5) 12 (28.6) 11 (34.4)
2 2 (1.3) 2 (2.6) 0 (0) 0 (0)
3 5 (3.3) 1 (1.3) 3 (7.1) 1 (3.1)
4 4 (2.7) 0 (0) 4 (9.5) 0 (0)
5 4 (2.7) 2 (2.6) 1 (2.4) 1 (3.1)
6 104 (69.3) 63 (82.9) 22 (52.4) 19 (59.4)
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often includes recommendations for mobility aides and 
minimising the impact of symptoms on daily mobility. 
The use of the STEMS in clinical practice will therefore 
provide an efficient and valid way in which to capture 
actual day to day baseline performance and any change, 
which is important to both clinicians and patients alike.
The new STEMS was highly correlated with the 
mobility aide usage reported by the FMS tool. How-
ever, unlike the distance requirements (5/50/500  m) 
reported in the FMS, the STEMS screens an individual’s 
performance across three environments (home, school/
work and community). In doing so, the STEMS consid-
ers how the combination of distance, speed of mobil-
ity, type of terrain and mobility demands may influence 
the need for a mobility aide. Furthermore, the STEMS 
captures patient reported symptoms such as pain and/
or fatigue that may impact upon mobility performance 
across differing environments. This is likely reflected 
by the significant but lower correlation between the 
STEMS mobility aide categories and normalised 
6MWT. The 6MWT, while a gold standard assessment 
in many clinical trials, is a measure of performance in 
a controlled environment under test conditions, not 
actual performance over time in a real world setting. 
Assessing capacity over a six minute period at a single 
point in time may also not have been sufficiently sensi-
tive or challenging to differentiate variations in walking 
distance that may become more evident across greater 
distances and time and vary day to day as symptoms 
vary.
a All participants b Participants with achondroplasia
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Fig. 1 STEMS mobility aide and symptom classifications of all participants and participants within each diagnostic category, across different 
environments
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In accordance with previous research, this study iden-
tified pain as highly prevalent in individuals with short 
stature [18, 19]. While the numbers of people report-
ing fatigue remained stable across the different environ-
ments, there was an increase in the numbers of people 
reporting either pain or pain and fatigue as the environ-
ment became more challenging. This suggests that pain 
alone is an issue but that pain and fatigue combined is 
the greater challenge for individuals with skeletal dyspla-
sia. This is the first report that considers fatigue as a sig-
nificant factor impacting on mobility of individuals with 
skeletal dysplasia of both short and typical stature.
Almost two thirds of individuals in the current cohort 
reported pain or pain and fatigue associated with mobil-
ity in the community. These results are slightly less than 
the 75% of individuals noting pain reported by Dhiman 
et  al. [19] in a recent study of pain in adults with skel-
etal dysplasia. Dhiman’s group described the severity 
and frequency of pain but did not link this to mobility 
or functional factors and did not include fatigue in their 
assessment. A much higher proportion of adults older 
than 51 years (44% in Dhiman’s study compared with 10% 
in the current study) may account for differences between 
the groups. However, despite over 62% percent of partici-
pants in this current study reporting pain alone or pain 
and fatigue when mobilising around the community, 
only twenty percent of individuals were scored as using 
a wheelchair or scooter across this environment. The 
majority of those utilising a wheelchair or power mobility 
scooter were children (68%), suggesting that a high pro-
portion of adults with a form of skeletal dysplasia report-
ing pain or pain and fatigue within the community are 
not utilising a mobility device that may assist with overall 
symptom reduction. This is commonly seen in the paedi-
atric population group where children will frequently use 
scooters to mobilise around the community as a mobility 
access strategy. The distinction between whether an aide 
was used to increase participation or ease symptomatol-
ogy was not ascertained as part of this trial. Use of the 
STEMS would allow clinicians to more accurately record 
symptoms associated with everyday mobility across dif-
ferent distances and environments, and evaluate changes 
associated with intervention, such as provision of mobil-
ity aide or surgery. The STEMS would also allow indi-
viduals and clinicians to more accurately reflect changes 
associated with aging or disease process and progression.
Significant associations were identified between 
number of symptoms and type of symptoms reported 
by both the combined and the achondroplasia groups 
when mobilising around the home and school/work, 























































Fig. 2 Normalised six minute walk distances covered by individuals based on symptomatology. The upper row in the panel demonstrates the type 
of symptom based on STEMS classification. The lower row indicates the number of symptoms. *indicate significant at p < 0.05 level
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and distances walked on the normalised 6MWT dis-
tance. However, there were no significant differences 
observed for either the combined or achondroplasia 
specific group linking number or type of symptoms 
across the community setting and distance covered 
in the 6MWT. The recognition that people report-
ing symptoms of pain, fatigue or both associated with 
mobility across the home and school/work environ-
ment, tended to mobilise shorter distances on the 
6MWT suggests that more significant body structure 
and function impairments or disease process may be 
present in these individuals.
A limitation to this study relates to the sample size 
for the total cohort and individual diagnostic group-
ings. Information was provided to both adults and chil-
dren with differing forms of skeletal dysplasia through 
clinical settings and through liaison with patient support 
groups such as the Short Statured People’s Association 
of Australia and the Osteogenesis Imperfecta Society of 
Australia. However, due to the relatively low numbers of 
individuals linked with patient support groups, it proved 
more challenging to recruit adults whilst children were 
more easily accessed through specialist tertiary public 
hospital clinics. Despite these challenges, over 44% of 
participants in this study were aged over 21  years, pro-
viding some access to information and any differing 
challenges reported by adults related to mobility and 
symptoms. To ensure representation across a variety of 
diagnoses and phenotypes, efforts were made to ensure 
that people with a variety of differing skeletal dysplasia 
forms were included in the total cohort.
The STEMS appears to be a useful new clinical tool to 
screen everyday mobility and associated symptoms of 
pain and/or fatigue in adults and children with a skel-
etal dysplasia. Inclusion of this tool will provide clini-
cians, families and individuals with the ability to record 
use of different mobility devices and identify symptoms 
associated with mobility across different environments. 
This will also allow for the monitoring of changes associ-
ated with aging or implementation of different or novel 
treatments, including drug therapies, which are emerg-
ing at a rapid pace for skeletal dysplasia [35]. A greater 
understanding of the links between functional mobility 
and associated symptomatology will be gained through 
ongoing research in this area. Further research is also 
necessary to understand the relative contribution that 
varying biomechanical, psychological or anthropometric 
features may have upon functional mobility and associ-
ated symptoms. Having a clearer understanding about 
links between anatomical impairments and presenta-
tions, and mobility will assist clinicians to better identify 
those individuals who would benefit from monitoring 
and intervention.
Conclusions
The Screening Tool for Everyday Mobility and Symp-
toms (STEMS) is a useful new tool to identify and 
record mobility aide use and self-reported symptoms 
across three environmental settings for adults and chil-
dren with skeletal dysplasia. The STEMS may assist cli-
nicians to monitor individuals for changes in functional 
mobility and symptoms over time, identify individu-
als who are functioning poorly compared to peers and 
need further assessment and to measure effectiveness 
of treatment interventions in both clinical and research 
settings.
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